Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RRM1/RIR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RRM1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site intact. |
View RRM1 Products |
| Gene Delivery | RRM1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View RRM1 Products |
| Benchmark Ab | Anti-RRM1 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IHC. |
View RRM1 Products |
| Validator | RRM1 siRNA Set For knockdown verification in drug resistance assays. |
View RRM1 Products |
| Related Target A | RRM2 The regulatory subunit of ribonucleotide reductase, forming the active holoenzyme complex with RRM1. |
View RRM2 Products |
| Related Target B | DCK Deoxycytidine Kinase; key rate-limiting enzyme in gemcitabine activation, highly relevant in RRM1-mediated resistance. |
View DCK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro holoenzyme reconstitution | Highly pure, structurally stable RRM1 and RRM2 proteins available for PPI and activity assays. |
| Allosteric site binding analysis | Sequence-verified wild-type proteins ensuring native conformation of activity and specificity sites. |
| Lack of Controls | Sequence-verified benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA included for target-specific knockdown validation. |
Live RRM1/RIR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Ribonucleotide Reductase M1 (RRM1/RIR) remains a cornerstone in overcoming chemoresistance in solid tumors. As a rate-limiting enzyme in dNTP synthesis, RRM1 overexpression is directly implicated in resistance to nucleoside analogs like gemcitabine and cytarabine. The race for RRM1 therapeutics is intensifying, with major players shifting focus from traditional nucleoside analogs to allosteric inhibitors and protein-protein interaction (PPI) disruptors that block the assembly of the active RRM1-RRM2 complex. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective non-nucleoside small molecules to minimize systemic hematological toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Academic Institutes, Biotech Startups | NSCLC, Pancreatic Cancer | Selectivity Assay (Need High-Purity RRM1 vs RRM2/RRM2B proteins) |
| PPI Inhibitors | Oncology-focused Biopharma | Gemcitabine-resistant Tumors | Holoenzyme Assembly Assay (Need high-purity RRM1 & RRM2) |
| RNA Interference (siRNA) | Gene Therapy Developers | Refractory Solid Tumors | Target Knockdown Validation (Need Sequence-verified siRNA & Antibodies) |